Fig. 1: GPR37 is underexpressed in ESCC and is associated with poor prognosis.

A Colony formation experiments were conducted to test the effectiveness of KYSE410R. The 0 Gy is used as the control group and a single-target multitarget model was used to fit the cell survival curve (n = 3). B Western blotting was used to detect GPR37 protein levels in KYSE410 and KYSE410R cells. C qRT‒PCR was used to detect GPR37 mRNA levels in KYSE410 and KYSE410R cells (n = 3). D GPR37 is low expressed in ESCC and EAC tissues. E Immunohistochemistry was used to analyze the expression level of GPR37 protein in ESCC tissues and adjacent normal tissues (magnification ×10 or ×40), and representative images were displayed; Scale bar: 100 μm. The right panel shows the immunohistochemical staining score for GPR37 in ESCC samples (n = 97). F Correlation between GPR37 protein levels and clinicopathological parameters of patients with ESCC (n = 97). Western blot (G) and qRT‒PCR (H) were used to detect the expression of GPR37 in fresh ESCC tissues and adjacent normal tissues. Kaplan–Meier analyzed the relationship between OS and GPR37 mRNA level of ESCC patients in TCGA ESCC (I), GSE53622 (J), and GSE5324 (K) datasets. L Kaplan–Meier analyzed the relationship between OS and GPR37 mRNA level in ESCC patients receiving radiotherapy in the TCGA database. M Kaplan–Meier analysis of the relationship between GPR37 protein expression and overall survival of patients with ESCC. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.